[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620781":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":26,"studyPopulation":26,"armGroups":33,"interventions":44,"overallOfficials":49,"centralContacts":56,"locations":61,"responsibleParty":75,"collaborators":77,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":26,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":26,"enrollmentInfo":92,"targetDuration":26,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":26,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Yale University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Attendance for MOUD","Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 30 days of enrollment.","Up to 30 days",[14,17,20,23],{"measure":10,"description":15,"timeFrame":16},"Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 31 to 90 days of enrollment.","Up to 90 days",{"measure":18,"description":19,"timeFrame":16},"Engagement with MOUD","Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of enrollment.",{"measure":21,"description":22,"timeFrame":12},"Overdose Events at 30 Days","A self-report of the number of subsequent overdose events within 30 days.",{"measure":24,"description":25,"timeFrame":16},"Overdose Events at 90 Days","A self-report of the number of subsequent overdose events within 90 days.",null,{"allocation":28,"interventionModel":29,"interventionModelDescription":26,"primaryPurpose":30,"observationalModel":26,"timePerspective":26,"maskingInfo":31},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":32,"maskingDescription":26,"whoMasked":26},"NONE",[34,40],{"label":35,"type":36,"description":37,"interventionNames":38},"RecoveryPad platform","EXPERIMENTAL","Participants randomized to RecoveryPad platform",[39],"Device: RecoveryPad platform",{"label":41,"type":42,"description":43,"interventionNames":26},"Treatment as usual","NO_INTERVENTION","Treatment as usual: referrals to harm reduction and other community resources that are already being given to individuals in the various community and healthcare settings from which these participants are being recruited.",[45],{"type":46,"name":35,"description":47,"armGroupLabels":48,"otherNames":26},"DEVICE","Telehealth platform to enhance motivation and engagement in treatment for OUD",[35],[50,53],{"name":51,"affiliation":5,"role":52},"Rebekah Heckmann, MD","PRINCIPAL_INVESTIGATOR",{"name":54,"affiliation":55,"role":52},"Nasim Sabounchi, PhD","CUNY Graduate School of Public Health & Health Policy",[57],{"name":51,"role":58,"phone":59,"phoneExt":26,"email":60},"CONTACT","(203) 737-8335","rebekah.heckmann@yale.edu",[62],{"facility":5,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":26},"RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-72.92816,41.30815,{"lat":73,"lon":72},{"type":76,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[78,81],{"name":79,"class":80},"National Institute on Drug Abuse (NIDA)","NIH",{"name":82,"class":6},"City University of New York, School of Public Health","100620781","a-clinical-trial-of-telehealth-treatment-for-opioid-use-disorders-100620781",false,"NCT07362082","A Clinical Trial of Telehealth Treatment for Opioid Use Disorders","A Randomized Clinical Trial of Telehealth Treatment for Opioid Use Disorders","Inclusion Criteria:\n\n* Can speak, read and write in English\n* Provision of signed and dated informed consent form\n* Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition\n* Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer)\n* Can provide a working email address OR be willing to create one\n\nExclusion Criteria:\n\n* Current use of buprenorphine, methadone, or naltrexone for a substance use disorder\n* Pregnancy\n* Known current suicide risk based on participant self-report\n* On parole or incarcerated at time of enrollment based on participant self-report","ALL","18 Years",{"count":93,"type":94},470,"ESTIMATED","INTERVENTIONAL",[97],"NA","This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.",[100],"Opioid Use Disorder","2026-09-18",{"date":103,"type":104},"2026-09-21","ACTUAL",{"date":106,"type":104},"2026-09-11",{"date":108,"type":94},"2027-12-01",{"name":5,"class":6},1]